VALIANT: Pegcetacoplan Shows Sustained Efficacy in C3G and IC-MPGN, With Carla Nester, MD
HCP Live,
New findings show pegcetacoplan maintained a 70% reduction in proteinuria over 52 weeks in adolescents with C3 glomerulopathy (C3…
Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial
Overview of attention for article published in Journal of the American Society of Nephrology, October 2025
